title: Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease.
abstract: A preclinical safety study was conducted to evaluate the short- and long-term toxicity of a recombinant adeno-associated virus serotype 8 (AAV2/8) vector that has been developed as an immune-modulatory adjunctive therapy to recombinant human acid α-glucosidase (rhGAA, Myozyme) enzyme replacement treatment (ERT) for patients with Pompe disease (AAV2/8-LSPhGAApA). The AAV2/8-LSPhGAApA vector at 1.6 × 10(13) vector particles/kg, after intravenous injection, did not cause significant short- or long-term toxicity. Recruitment of CD4(+) (but not CD8(+)) lymphocytes to the liver was elevated in the vector-dosed male animals at study day (SD) 15, and in group 8 animals at SD 113, in comparison to their respective control animals. Administration of the vector, either prior to or after the one ERT injection, uniformly prevented the hypersensitivity induced by subsequent ERT in males, but not always in female animals. The vector genome was sustained in all tissues through 16-week postdosing, except for in blood with a similar tissue tropism between males and females. Administration of the vector alone, or combined with the ERT, was effective in producing significantly increased GAA activity and consequently decreased glycogen accumulation in multiple tissues, and the urine biomarker, Glc4, was significantly reduced. The efficacy of the vector (or with ERT) was better in males than in females, as demonstrated both by the number of tissues showing significantly effective responses and the extent of response in a given tissue. Given the lack of toxicity for AAV2/8LSPhGAApA, further consideration of clinical translation is warranted in Pompe disease.
authors.affiliation: Applied Toxicology and Gene Therapy Pharm/Tox Program, Lovelace Respiratory Research Institute , Albuquerque, New Mexico, USA.
authors.forename: Gensheng
authors.initials: G
authors.lastname: Wang
authors.affiliation: Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center , Durham, North Carolina, USA.
authors.forename: Sarah P
authors.initials: SP
authors.lastname: Young
authors.affiliation: Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center , Durham, North Carolina, USA.
authors.forename: Deeksha
authors.initials: D
authors.lastname: Bali
authors.affiliation: Applied Toxicology and Gene Therapy Pharm/Tox Program, Lovelace Respiratory Research Institute , Albuquerque, New Mexico, USA.
authors.forename: Julie
authors.initials: J
authors.lastname: Hutt
authors.affiliation: Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center , Durham, North Carolina, USA.
authors.forename: Songtao
authors.initials: S
authors.lastname: Li
authors.affiliation: Applied Toxicology and Gene Therapy Pharm/Tox Program, Lovelace Respiratory Research Institute , Albuquerque, New Mexico, USA.
authors.forename: Janet
authors.initials: J
authors.lastname: Benson
authors.affiliation: Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center , Durham, North Carolina, USA.
authors.forename: Dwight D
authors.initials: DD
authors.lastname: Koeberl